Polaryx Therapeutics (NASDAQ:PLYX) Issues Earnings Results

Polaryx Therapeutics (NASDAQ:PLYX) announced its earnings results on Thursday. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02), FiscalAI reports.

Polaryx Therapeutics Price Performance

Shares of PLYX stock traded down $0.07 during mid-day trading on Thursday, hitting $1.88. The stock had a trading volume of 9,878 shares, compared to its average volume of 24,078. Polaryx Therapeutics has a 12-month low of $1.69 and a 12-month high of $48.91. The firm’s 50-day moving average is $1.97 and its two-hundred day moving average is $3.08.

Wall Street Analysts Forecast Growth

PLYX has been the subject of several research analyst reports. Wall Street Zen upgraded Polaryx Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Weiss Ratings upgraded shares of Polaryx Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, November 2nd. Finally, Raymond James Financial initiated coverage on shares of Polaryx Therapeutics in a report on Thursday, August 13th. They issued a “strong-buy” rating and a $6.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Polaryx Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.67.

About Polaryx Therapeutics

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.